Research graph
References from Stereotactic Body Radiation Therapy in Oligometastatic Castration-resistant Prostate Cancer: Time to Move from Signals to Phase 3 Trial Evidence. Local targets link to admitted publications; unresolved targets remain external evidence.
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
10.1016/s1470-2045(26)00178-6 · 2026 · External reference
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
10.1016/s1470-2045(25)00351-1 · 2025 · External reference
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
10.1016/s1470-2045(25)00658-8 · 2026 · External reference
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2026.01.015 · 2026 · External reference
Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial
10.1001/jamaoncol.2017.5808 · 2018 · External reference
